Literature DB >> 19150627

Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment.

Sulayman D Dib-Hajj1, Alexander M Binshtok, Theodore R Cummins, Michael F Jarvis, Tarek Samad, Katharina Zimmermann.   

Abstract

Pain is a major unmet medical need which has been causally linked to changes in sodium channel expression, modulation, or mutations that alter channel gating properties or current density in nociceptor neurons. Voltage-gated sodium channels activate (open) then rapidly inactivate in response to a depolarization of the plasma membrane of excitable cells allowing the transient flow of sodium ions thus generating an inward current which underlies the generation and conduction of action potentials (AP) in these cells. Activation and inactivation, as well as other gating properties, of sodium channel isoforms have different kinetics and voltage-dependent properties, so that the ensemble of channels that are present determine the electrogenic properties of specific neurons. Biophysical and pharmacological studies have identified the peripheral-specific sodium channels Na(v)1.7, Na(v)1.8 and Na(v)1.9 as particularly important in the pathophysiology of different pain syndromes, and isoform-specific blockers of these channels or targeting their modulators hold the promise of a future effective therapy for treatment of pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19150627     DOI: 10.1016/j.brainresrev.2008.12.005

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  52 in total

Review 1.  Targeting voltage-gated sodium channels for treatment for chronic visceral pain.

Authors:  Fei-Hu Qi; You-Lang Zhou; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Differential expression of sodium channel β subunits in dorsal root ganglion sensory neurons.

Authors:  Cojen Ho; Juan Zhao; Steven Malinowski; Mohamed Chahine; Michael E O'Leary
Journal:  J Biol Chem       Date:  2012-03-09       Impact factor: 5.157

3.  Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.

Authors:  Ken McCormack; Sonia Santos; Mark L Chapman; Douglas S Krafte; Brian E Marron; Christopher W West; Michael J Krambis; Brett M Antonio; Shannon G Zellmer; David Printzenhoff; Karen M Padilla; Zhixin Lin; P Kay Wagoner; Nigel A Swain; Paul A Stupple; Marcel de Groot; Richard P Butt; Neil A Castle
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

Review 4.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 5.  Subtype-selective targeting of voltage-gated sodium channels.

Authors:  Steve England; Marcel J de Groot
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

6.  Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and review.

Authors:  D P Roberson; A M Binshtok; F Blasl; B P Bean; C J Woolf
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Authors:  Brian A Sparling; S Yi; J Able; H Bregman; Erin F DiMauro; R S Foti; H Gao; A Guzman-Perez; H Huang; M Jarosh; T Kornecook; J Ligutti; B C Milgram; B D Moyer; B Youngblood; V L Yu; M M Weiss
Journal:  Medchemcomm       Date:  2016-12-02       Impact factor: 3.597

8.  MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

Review 9.  Ion channels as drug targets in central nervous system disorders.

Authors:  A M Waszkielewicz; A Gunia; N Szkaradek; K Słoczyńska; S Krupińska; H Marona
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

10.  Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1/2 activation.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Mikihiro Matsumoto; Natsuki Kato; Ryo-Ta Asano; Motohiro Imano; Takao Satou; Shozo Nishida
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.